secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001171843-23-000899
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics appoints David Wurzer to Board and as Audit Committee Chairman
--------------------------------------------------------------------------------

- David Wurzer appointed as Class III director effective Feb 8, 2023.
- Wurzer named Chairman of Audit Committee; independent and audit committee financial expert.
- Compensation: $45,000 cash retainer plus $10,000 for Audit Chair; 50,000-share option award vesting over 4 years.
- Wurzer is CFO of Enko Chem, Inc.; no family relationships or reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323000899/0001171843-23-000899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323000899/f8k_021023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-000899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer